Osteoporosis and fractures in liver disease: Relevance, pathogenesis and therapeutic implications

World Journal of Gastroenterology

Volumn 20, Issue 28, 2014, Pages 9427-9438

  Nakchbandi, Inaam A ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

Calcium; Fibronectin; Fracture; Insulin like growth factor I; Liver disease; Osteoporosis; Pathogenesis; Prevalence; Therapy; Vitamin D

Indexed keywords

BILIRUBIN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; FIBRONECTIN; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PENICILLAMINE; PHOSPHATE; SEX HORMONE; SOMATOMEDIN; SOMATOMEDIN C; URSODEOXYCHOLIC ACID; VITAMIN D; BONE DENSITY CONSERVATION AGENT;

ANTIVIRAL THERAPY; AUTOIMMUNE LIVER DISEASE; BONE DENSITY; BONE MATRIX; BONE MINERALIZATION; BONE REMODELING; CALCIUM ABSORPTION; CHOLESTASIS; CHRONIC LIVER DISEASE; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; FRAGILITY FRACTURE; GRAFT RECIPIENT; HEMOCHROMATOSIS; HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; IRON OVERLOAD; LIVER CIRRHOSIS; LIVER DISEASE; LIVER GRAFT; LIVER TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PHOSPHATE METABOLISM; REVIEW; RISK ASSESSMENT; VIRUS HEPATITIS; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION; WILSON DISEASE; ANIMAL; BONE; DIET SUPPLEMENTATION; LIVER; LIVER DISEASES; METABOLISM; OSTEOPOROTIC FRACTURES; PATHOLOGY; PREDICTIVE VALUE; PREVALENCE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CALCIUM; DIETARY SUPPLEMENTS; HUMANS; LIVER; LIVER DISEASES; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PREDICTIVE VALUE OF TESTS; PREVALENCE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VITAMIN D;

EID: 84908894752     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i28.9427     Document Type: Review

References (137)

1. Ried IR. Overview of pathogenesis. In: Rosen CJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 8th ed. Ames: John Wiley & Sons, 2013: 357-360
2. Cooke AM. Osteoporosis. Lancet 1955; 268: 877-82; contd [PMID: 14368895]
3. Neale G. Generalised disorders of bone associated with disease of the gastro-intestinal tract. Ir J Med Sci 1974; 0: suppl: 57-suppl: 63 [PMID: 4604501]
4. Nordin BE. Treatment of postmenopausal osteoporosis. Drugs 1979; 18: 484-492 [PMID: 391532]
5. Broadus A. Mineral balance and homeostasis. In: Favus M, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 1999: 74-80
6. Robey PG, Boskey AL. The biochemistry of bone. In: Marcus R, Feldman D, Kelsey J, editors. Osteoporosis. San Diego: Academic Press, 1996: 95-183
7. Kawai M, Rosen CJ. The insulin-like growth factor system in bone: basic and clinical implications. Endocrinol Metab Clin North Am 2012; 41: 323-33, vi [PMID: 22682633 DOI: 10.1016/j.ecl.2012.04.013]
8. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843: 1-129 [PMID: 7941614]
9. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19: 385-397 [PMID: 18292978 DOI: 10.1007/s00198-007-0543-5]
10. Office of the Surgeon General (US). Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville (MD): Office of the Surgeon General (US), 2004 [PMID: 20945569]
11. Leibson CL, Tosteson AN, Gabriel SE, Ransom JE, Melton LJ. Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc 2002; 50: 1644-1650 [PMID: 12366617]
12. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013; 58: 593-608 [PMID: 23419824 DOI: 10.1016/j.jhep.2012.12.005]
13. Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003; 125: 941-966 [PMID: 12949738]
14. Nakchbandi IA, van der Merwe SW. Current understanding of osteoporosis associated with liver disease. Nat Rev Gastroenterol Hepatol 2009; 6: 660-670 [PMID: 19881518 DOI: 10.1038/nrgastro.2009.166]
15. Bonewald LF. Osteocytes. In: Rosen CJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 8th ed. Ames: John Wiley & Sons, 2013: 34-41
16. Cuthbert JA, Pak CY, Zerwekh JE, Glass KD, Combes B. Bone disease in primary biliary cirrhosis: increased bone resorption and turnover in the absence of osteoporosis or osteomalacia. Hepatology 1984; 4: 1-8 [PMID: 6693061]
17. Diamond TH, Stiel D, Lunzer M, McDowall D, Eckstein RP, Posen S. Hepatic osteodystrophy. Static and dynamic bone histomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease. Gastroenterology 1989; 96: 213-221 [PMID: 2783312]
18. Guichelaar MM, Malinchoc M, Sibonga J, Clarke BL, Hay JE. Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry. Hepatology 2002; 36: 895-903 [PMID: 12297836]
19. Hodgson SF, Dickson ER, Wahner HW, Johnson KA, Mann KG, Riggs BL. Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med 1985; 103: 855-860 [PMID: 4062087]
20. Tsuneoka K, Tameda Y, Takase K, Nakano T. Osteodystrophy in patients with chronic hepatitis and liver cirrhosis. J Gastroenterol 1996; 31: 669-678 [PMID: 8887033]
21. van der Merwe SW, Conradie MM, Bond R, Olivier BJ, Fritz E, Nieuwoudt M, Delport R, Slavik T, Engelbrecht G, Kahn D, Shephard EG, Kotze MJ, de Villiers NP, Hough S. Effect of rapamycin on hepatic osteodystrophy in rats with portasystemic shunting. World J Gastroenterol 2006; 12: 4504-4510 [PMID: 16874862]
22. van der Merwe SW, van den Bogaerde JB, Goosen C, Maree FF, Milner RJ, Schnitzler CM, Biscardi A, Mesquita JM, Engelbrecht G, Kahn D, Fevery J. Hepatic osteodystrophy in rats results mainly from portasystemic shunting. Gut 2003; 52: 580-585 [PMID: 12631673]
23. de Vernejoul MC, Pointillart A, Golenzer CC, Morieux C, Bielakoff J, Modrowski D, Miravet L. Effects of iron overload on bone remodeling in pigs. Am J Pathol 1984; 116: 377-384 [PMID: 6476075]
24. Diamond T, Pojer R, Stiel D, Alfrey A, Posen S. Does iron affect osteoblast function? Studies in vitro and in patients with chronic liver disease. Calcif Tissue Int 1991; 48: 373-379 [PMID: 2070271]
25. Wilson T, Katz JM, Gray DH. Inhibition of active bone resorption by copper. Calcif Tissue Int 1981; 33: 35-39 [PMID: 6780154]
26. Casado JL, Bañon S, Andrés R, Perez-Elías MJ, Moreno A, Moreno S. Prevalence of causes of secondary osteoporosis and contribution to lower bone mineral density in HIVinfected patients. Osteoporos Int 2014; 25: 1071-1079 [PMID: 24057480 DOI: 10.1007/s00198-013-2506-3]
27. Corazza GR, Trevisani F, Di Stefano M, De Notariis S, Veneto G, Cecchetti L, Minguzzi L, Gasbarrini G, Bernardi M. Early increase of bone resorption in patients with liver cirrhosis secondary to viral hepatitis. Dig Dis Sci 2000; 45: 1392-1399 [PMID: 10961720]
28. Hofmann WP, Kronenberger B, Bojunga J, Stamm B, Herrmann E, Bücker A, Mihm U, von Wagner M, Zeuzem S, Sarrazin C. Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon alpha and ribavirin therapy. J Viral Hepat 2008; 15: 790-796 [PMID: 18673425 DOI: 10.1111/j.1365-2893.2008.01038.x]
29. Nøjgaard C, Johansen JS, Krarup HB, Holten-Andersen M, Møller A, Bendtsen F; Danish Viral Hepatitis Study Group. Effect of antiviral therapy on markers of fibrogenesis in patients with chronic hepatitis C. Scand J Gastroenterol 2003; 38: 659-665 [PMID: 12825876]
30. Schiefke I, Fach A, Wiedmann M, Aretin AV, Schenker E, Borte G, Wiese M, Moessner J. Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol 2005; 11: 1843-1847 [PMID: 15793878]
31. Hay JE. Bone disease in cholestatic liver disease. Gastroenterology 1995; 108: 276-283 [PMID: 7806050]
32. Stellon AJ, Davies A, Compston J, Williams R. Osteoporosis in chronic cholestatic liver disease. Q J Med 1985; 57: 783-790 [PMID: 2934760]
33. Stellon AJ, Webb A, Compston J, Williams R. Low bone turnover state in primary biliary cirrhosis. Hepatology 1987; 7: 137-142 [PMID: 3804193]
34. Wariaghli G, Allali F, El Maghraoui A, Hajjaj-Hassouni N. Osteoporosis in patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2010; 22: 1397-1401 [PMID: 20926953 DOI: 10.1097/MEG.0b013e3283405939]
35. Janes CH, Dickson ER, Okazaki R, Bonde S, McDonagh AF, Riggs BL. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 1995; 95: 2581-2586 [PMID: 7769100]
36. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, Curtis JR, Furst DE, McMahon M, Patkar NM, Volkmann E, Saag KG. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62: 1515-1526 [PMID: 20662044 DOI: 10.1002/acr.20295]
37. El-Husseini A, Sabry A, Hassan R, Sobh M. Effect of chronic hepatitis C virus infection on bone mineral density in pediatric renal transplant recipients. Saudi J Kidney Dis Transpl 2013; 24: 917-924 [PMID: 24029255]
38. Boonchaya-anant P, Hardy E, Borg BB, Burshell AL. Bone mineral density in patients with nonalcoholic steatohepatitis among end-stage liver disease patients awaiting liver transplantation. Endocr Pract 2013; 19: 414-419 [PMID: 23337159 DOI: 10.4158/EP12319.OR]
39. Lo Re V, Volk J, Newcomb CW, Yang YX, Freeman CP, Hennessy S, Kostman JR, Tebas P, Leonard MB, Localio AR. Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection. Hepatology 2012; 56: 1688-1698 [PMID: 22619086 DOI: 10.1002/hep.25866]
40. Guañabens N, Cerdá D, Monegal A, Pons F, Caballería L, Peris P, Parés A. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology 2010; 138: 2348-2356 [PMID: 20178794 DOI: 10.1053/j.gastro.2010.02.016]
41. Smith DL, Shire NJ, Watts NB, Schmitter T, Szabo G, Zucker SD. Hyperbilirubinemia is not a major contributing factor to altered bone mineral density in patients with chronic liver disease. J Clin Densitom 2006; 9: 105-113 [PMID: 16731439]
42. Valenti L, Varenna M, Fracanzani AL, Rossi V, Fargion S, Sinigaglia L. Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int 2009; 20: 549-555 [PMID: 18661088 DOI: 10.1007/s00198-008-0701-4]
43. Hegedus D, Ferencz V, Lakatos PL, Meszaros S, Lakatos P, Horvath C, Szalay F. Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease. J Bone Miner Res 2002; 17: 1961-1967 [PMID: 12412803 DOI: 10.1359/jbmr.2002.17.11.1961]
44. Selimoglu MA, Ertekin V, Doneray H, Yildirim M. Bone mineral density of children with Wilson disease: efficacy of penicillamine and zinc therapy. J Clin Gastroenterol 2008; 42: 194-198 [PMID: 18209591 DOI: 10.1097/MCG.0b013e318032388d]
45. Hagdrup H, Serup J, Tvedegaard E. Does long-term treatment with D-penicillamine alter calcium and phosphorus metabolism in patients with systemic sclerosis? Acta Derm Venereol 1983; 63: 447-449 [PMID: 6197850]
46. Pfeiffer RF. Wilson's Disease. Semin Neurol 2007; 27: 123-132 [PMID: 17390257 DOI: 10.1055/s-2007-971173]
47. Bjøro K, Brandsaeter B, Wiencke K, Bjøro T, Godang K, Bollerslev J, Schrumpf E. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease. Scand J Gastroenterol 2003; 38: 320-327 [PMID: 12737449]
48. Dodidou P, Bruckner T, Hosch S, Haass M, Klar E, Sauer P, Ziegler R, Leidig-Bruckner G. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation. Osteoporos Int 2003; 14: 82-89 [PMID: 12577189]
49. Eastell R, Dickson ER, Hodgson SF, Wiesner RH, Porayko MK, Wahner HW, Cedel SL, Riggs BL, Krom RA. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 1991; 14: 296-300 [PMID: 1860685]
50. Karges W, Trautwein C. Liver transplantation and osteoporosis: securing "bone-fied" success. Liver Transpl 2006; 12: 1322-1323 [PMID: 16933232]
51. Leidig-Bruckner G, Hosch S, Dodidou P, Ritschel D, Conradt C, Klose C, Otto G, Lange R, Theilmann L, Zimmerman R, Pritsch M, Ziegler R. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet 2001; 357: 342-347 [PMID: 11210996]
52. Reeves HL, Francis RM, Manas DM, Hudson M, Day CP. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Transpl Surg 1998; 4: 404-409 [PMID: 9724478]
53. Li M, Xu Y, Xu M, Ma L, Wang T, Liu Y, Dai M, Chen Y, Lu J, Liu J, Bi Y, Ning G. Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middleaged and elderly Chinese. J Clin Endocrinol Metab 2012; 97: 2033-2038 [PMID: 22466338 DOI: 10.1210/jc.2011-3010]
54. Jeon YK, Lee JG, Kim SS, Kim BH, Kim SJ, Kim YK, Kim IJ. Association between bone mineral density and metabolic syndrome in pre- and postmenopausal women. Endocr J 2011; 58: 87-93 [PMID: 21242648]
55. Moon SS, Lee YS, Kim SW. Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women. Endocrine 2012; 42: 423-429 [PMID: 22407492 DOI: 10.1007/s12020-012-9639-6]
56. Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, Le-Roith D. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest 2002; 110: 771-781 [PMID: 12235108]
57. Bentmann A, Kawelke N, Moss D, Zentgraf H, Bala Y, Berger I, Gasser JA, Nakchbandi IA. Circulating fibronectin affects bone matrix, whereas osteoblast fibronectin modulates osteoblast function. J Bone Miner Res 2010; 25: 706-715 [PMID: 19821765 DOI: 10.1359/jbmr.091011]
58. Kawelke N, Bentmann A, Hackl N, Hager HD, Feick P, Geursen A, Singer MV, Nakchbandi IA. Isoform of fibronectin mediates bone loss in patients with primary biliary cirrhosis by suppressing bone formation. J Bone Miner Res 2008; 23: 1278-1286 [PMID: 18348696]
59. Sun BH, Mitnick M, Eielson C, Yao GQ, Paliwal I, Insogna K. Parathyroid hormone increases circulating levels of fibronectin in vivo: modulating effect of ovariectomy. Endocrinology 1997; 138: 3918-3924 [PMID: 9275082]
60. Masiukiewicz US, Mitnick M, Grey AB, Insogna KL. Estrogen modulates parathyroid hormone-induced interleukin-6 production in vivo and in vitro. Endocrinology 2000; 141: 2526-2531 [PMID: 10875254]
61. Farrugia W, Melick RA. Metabolism of osteocalcin. Calcif Tissue Int 1986; 39: 234-238 [PMID: 3098386]
62. Hynes R. Distribution of Fibronectins in vivo: Plasma. In: Rich A, editor. Fibronectins. New York: Springer, 1990: 27-30
63. Hackl NJ, Bersch C, Feick P, Antoni C, Franke A, Singer MV, Nakchbandi IA. Circulating fibronectin isoforms predict the degree of fibrosis in chronic hepatitis C. Scand J Gastroenterol 2010; 45: 349-356 [PMID: 20017652 DOI: 10.310 9/00365520903490606]
64. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, Le-Roith D. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 1999; 96: 7324-7329 [PMID: 10377413]
65. Elis S, Courtland HW, Wu Y, Rosen CJ, Sun H, Jepsen KJ, Majeska RJ, Yakar S. Elevated serum levels of IGF-1 are sufficient to establish normal body size and skeletal properties even in the absence of tissue IGF-1. J Bone Miner Res 2010; 25: 1257-1266 [PMID: 20200935 DOI: 10.1002/jbmr.20]
66. Ghiron LJ, Thompson JL, Holloway L, Hintz RL, Butterfield GE, Hoffman AR, Marcus R. Effects of recombinant insulinlike growth factor-I and growth hormone on bone turnover in elderly women. J Bone Miner Res 1995; 10: 1844-1852 [PMID: 8619364 DOI: 10.1002/jbmr.5650101203]
67. Nakchbandi IA, Lang R, Kinder B, Insogna KL. The role of the receptor activator of nuclear factor-kappaB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism. J Clin Endocrinol Metab 2008; 93: 967-973 [PMID: 18073309 DOI: 10.1210/jc.2007-1645]
68. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000; 15: 2-12 [PMID: 10646108 DOI: 10.1080/1404 1040009362546]
69. Moschen AR, Kaser A, Stadlmann S, Millonig G, Kaser S, Mühllechner P, Habior A, Graziadei I, Vogel W, Tilg H. The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol 2005; 43: 973-983 [PMID: 16143421 DOI: 10.1016/j.jhep.2005.05.034]
70. Saito-Yabe M, Kasuya Y, Yoshigae Y, Yamamura N, Suzuki Y, Fukuda N, Honma M, Yano K, Mochizuki S, Okada F, Okada A, Nagayama Y, Tsuda E, Fischer T, Höpner U, Zaja S, Mueller J, Okada J, Kurihara A, Ikeda T, Okazaki O. PEGylation of osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF) results in decreased uptake into rats and human liver. J Pharm Pharmacol 2010; 62: 985-994 [PMID: 20663032 DOI: 10.1111/j.2042-7158.2010.01120.x]
71. Nakchbandi IA, Mitnick MA, Lang R, Gundberg C, Kinder B, Insogna K. Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2002; 87: 4946-4951 [PMID: 12414855]
72. Nakchbandi IA, Mitnick MA, Masiukiewicz US, Sun BH, Insogna KL. IL-6 negatively regulates IL-11 production in vitro and in vivo. Endocrinology 2001; 142: 3850-3856 [PMID: 11517162]
73. Hughes FJ, Howells GL. Interleukin-6 inhibits bone formation in vitro. Bone Miner 1993; 21: 21-28 [PMID: 8324417]
74. Li Y, Bäckesjö CM, Haldosén LA, Lindgren U. IL-6 receptor expression and IL-6 effects change during osteoblast differentiation. Cytokine 2008; 43: 165-173 [PMID: 18555695 DOI: 10.1016/j.cyto.2008.05.007]
75. Erices A, Conget P, Rojas C, Minguell JJ. Gp130 activation by soluble interleukin-6 receptor/interleukin-6 enhances osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. Exp Cell Res 2002; 280: 24-32 [PMID: 12372336]
76. Neve A, Corrado A, Cantatore FP. Osteoblast physiology in normal and pathological conditions. Cell Tissue Res 2011; 343: 289-302 [PMID: 21120535 DOI: 10.1007/s00441-010-1086-1]
77. Shimada M, Matsumata T, Taketomi A, Shirabe K, Yamamoto K, Takenaka K, Sugimachi K. The role of interleukin-6, interleukin-16, tumor necrosis factor-alpha and endotoxin in hepatic resection. Hepatogastroenterology 1995; 42: 691-697 [PMID: 8751236]
78. Ding Y, Zhao L, Mei H, Huang ZH, Zhang SL. Alterations of biliary biochemical constituents and cytokines in infantile hepatitis syndrome. World J Gastroenterol 2006; 12: 7038-7041 [PMID: 17109502]
79. Axmann R, Böhm C, Krönke G, Zwerina J, Smolen J, Schett G. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum 2009; 60: 2747-2756 [PMID: 19714627 DOI: 10.1002/art.24781]
80. Dhillon S. Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis. BioDrugs 2014; 28: 75-106 [PMID: 24255004 DOI: 10.1007/s40259-013-0076-8]
81. Karan MA, Erten N, Tascioglu C, Karan A, Sindel D, Dilsen G. Osteodystrophy in posthepatitic cirrhosis. Yonsei Med J 2001; 42: 547-552 [PMID: 11675684]
82. Weinstein RS, Parfitt AM, Marcus R, Greenwald M, Crans G, Muchmore DB. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporos Int 2003; 14: 814-822 [PMID: 14610642]
83. Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med 2007; 357: 1229-1237 [PMID: 17881754 DOI: 10.1056/NEJMcp070677]
84. Zumoff B, Fishman J, Gallagher TF, Hellman L. Estradiol metabolism in cirrhosis. J Clin Invest 1968; 47: 20-25 [PMID: 16695941 DOI: 10.1172/JCI105709]
85. Kreek MJ. Female sex steroids and cholestasis. Semin Liver Dis 1987; 7: 8-23 [PMID: 3296217]
86. Ormarsdóttir S, Mallmin H, Naessén T, Petrén-Mallmin M, Broomé U, Hultcrantz R, Lööf L. An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis. J Intern Med 2004; 256: 63-69 [PMID: 15189367]
87. Grossmann M, Hoermann R, Gani L, Chan I, Cheung A, Gow PJ, Li A, Zajac JD, Angus P. Low testosterone levels as an independent predictor of mortality in men with chronic liver disease. Clin Endocrinol (Oxf) 2012; 77: 323-328 [PMID: 22280063 DOI: 10.1111/j.1365-2265.2012.04347.x]
88. Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag 2009; 5: 427-448 [PMID: 19707253]
89. Søe KL, Søe M, Gluud C. Liver pathology associated with the use of anabolic-androgenic steroids. Liver 1992; 12: 73-79 [PMID: 1535676]
90. Guañabens N, Parés A, Ros I, Caballería L, Pons F, Vidal S, Monegal A, Peris P, Rodés J. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol 2005; 42: 573-577 [PMID: 15763344 DOI: 10.1016/j.jhep.2004.11.035]
91. Guichelaar MM, Kendall R, Malinchoc M, Hay JE. Bone mineral density before and after OLT: long-term followup and predictive factors. Liver Transpl 2006; 12: 1390-1402 [PMID: 16933236 DOI: 10.1002/lt.20874]
92. Compston JE, Thompson RP. Intestinal absorption of 25-hydroxyvitamin D and osteomalacia in primary biliary cirrhosis. Lancet 1977; 1: 721-724 [PMID: 66519]
93. Hodgson SF, Dickson ER, Eastell R, Eriksen EF, Bryant SC, Riggs BL. Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis. Bone 1993; 14: 819-827 [PMID: 8155404]
94. van Leeuwen JP, van Driel M, van den Bemd GJ, Pols HA. Vitamin D control of osteoblast function and bone extracellular matrix mineralization. Crit Rev Eukaryot Gene Expr 2001; 11: 199-226 [PMID: 11693961]
95. Lindor KD, Janes CH, Crippin JS, Jorgensen RA, Dickson ER. Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? Hepatology 1995; 21: 389-392 [PMID: 7843710]
96. Stellon AJ, Webb A, Compston J, Williams R. Lack of osteomalacia in chronic cholestatic liver disease. Bone 1986; 7: 181-185 [PMID: 3768195]
97. Nair S. Vitamin d deficiency and liver disease. Gastroenterol Hepatol (N Y) 2010; 6: 491-493 [PMID: 20978551]
98. Mitra R. Adverse effects of corticosteroids on bone metabolism: a review. PM R 2011; 3: 466-71; quiz 471 [PMID: 21570035 DOI: 10.1016/j.pmrj.2011.02.017]
99. Skversky AL, Kumar J, Abramowitz MK, Kaskel FJ, Melamed ML. Association of glucocorticoid use and low 25-hydroxyvitamin D levels: results from the National Health and Nutrition Examination Survey (NHANES): 2001-2006. J Clin Endocrinol Metab 2011; 96: 3838-3845 [PMID: 21956424 DOI: 10.1210/jc.2011-1600]
100. Angulo P, Therneau TM, Jorgensen A, De Sotel CK, Egan KS, Dickson ER, Hay JE, Lindor KD. Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J Hepatol 1998; 29: 729-735 [PMID: 9833910]
101. Asomaning K, Bertone-Johnson ER, Nasca PC, Hooven F, Pekow PS. The association between body mass index and osteoporosis in patients referred for a bone mineral density examination. J Womens Health (Larchmt) 2006; 15: 1028-1034 [PMID: 17125421]
102. Collier J. Bone disorders in chronic liver disease. Hepatology 2007; 46: 1271-1278 [PMID: 17886334]
103. Hay JE, Guichelaar MM. Evaluation and management of osteoporosis in liver disease. Clin Liver Dis 2005; 9: 747-66, viii [PMID: 16207574]
104. Lakatos PL, Bajnok E, Tornai I, Folhoffer A, Horvath A, Lakatos P, Habior A, Szalay F. Insulin-like growth factor I gene microsatellite repeat, collagen type Ialpha1 gene Sp1 polymorphism, and bone disease in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2004; 16: 753-759 [PMID: 15256976]
105. Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 2002; 35: 126-131 [PMID: 11786968]
106. Parés A, Guañabens N. Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment. Clin Liver Dis 2008; 12: 407-24; x [PMID: 18456188]
107. Parés A, Guañabens N, Rodés J. Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2005; 17: 311-315 [PMID: 15716655]
108. Lakatos LP, Bajnok E, Hegedus D, Tóth T, Lakatos P, Szalay F. Vitamin D receptor, oestrogen receptor-alpha gene and interleukin-1 receptor antagonist gene polymorphisms in Hungarian patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2002; 14: 733-740 [PMID: 12169981]
109. Springer JE, Cole DE, Rubin LA, Cauch-Dudek K, Harewood L, Evrovski J, Peltekova VD, Heathcote EJ. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 2000; 118: 145-151 [PMID: 10611163]
110. Parés A, Guañabens N, Alvarez L, De Osaba MJ, Oriola J, Pons F, Caballería L, Monegal A, Salvador G, Jo J, Peris P, Rivera F, Ballesta AM, Rodés J. Collagen type Ialpha1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. Hepatology 2001; 33: 554-560 [PMID: 11230734]
111. de Carvalho SC, Muniz MT, Siqueira MD, Siqueira ER, Gomes AV, Silva KA, Bezerra LC, D'Almeida V, de Oliveira CP, Pereira LM. Plasmatic higher levels of homocysteine in non-alcoholic fatty liver disease (NAFLD). Nutr J 2013; 12: 37 [PMID: 23547829 DOI: 10.1186/1475-2891-12-37]
112. Lubec B, Fang-Kircher S, Lubec T, Blom HJ, Boers GH. Evidence for McKusick's hypothesis of deficient collagen crosslinking in patients with homocystinuria. Biochim Biophys Acta 1996; 1315: 159-162 [PMID: 8611653]
113. Herrmann M, Widmann T, Colaianni G, Colucci S, Zallone A, Herrmann W. Increased osteoclast activity in the presence of increased homocysteine concentrations. Clin Chem 2005; 51: 2348-2353 [PMID: 16195358 DOI: 10.1373/clinchem.2005.053363]
114. Sakamoto W, Isomura H, Fujie K, Deyama Y, Kato A, Nishihira J, Izumi H. Homocysteine attenuates the expression of osteocalcin but enhances osteopontin in MC3T3-E1 preosteoblastic cells. Biochim Biophys Acta 2005; 1740: 12-16 [PMID: 15878736 DOI: 10.1016/j.bbadis.2005.03.004]
115. Yang J, Hu X, Zhang Q, Cao H, Wang J, Liu B. Homocysteine level and risk of fracture: A meta-analysis and systematic review. Bone 2012; 51: 376-382 [PMID: 22749888 DOI: 10.1016/j.bone.2012.05.024]
116. Gerdhem P, Ivaska KK, Isaksson A, Pettersson K, Väänänen HK, Obrant KJ, Akesson K. Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women. J Bone Miner Res 2007; 22: 127-134 [PMID: 17032146 DOI: 10.1359/jbmr.061003]
117. Olivier BJ, Schoenmaker T, Mebius RE, Everts V, Mulder CJ, van Nieuwkerk KM, de Vries TJ, van der Merwe SW. Increased osteoclast formation and activity by peripheral blood mononuclear cells in chronic liver disease patients with osteopenia. Hepatology 2008; 47: 259-267 [PMID: 18022900]
118. Diez Ruiz A, Santos Perez JL, Lopez Martinez G, Gonzalez Calvín J, Gil Extremera B, Gutierrez Gea F. Tumour necrosis factor, interleukin-1 and interleukin-6 in alcoholic cirrhosis. Alcohol Alcohol 1993; 28: 319-323 [PMID: 8352843]
119. García-Valdecasas-Campelo E, González-Reimers E, Santolaria-Fernández F, De la Vega-Prieto MJ, Milena-Abril A, Sánchez-Pérez MJ, Martínez-Riera A, Gómez-Rodríguez Mde L. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease. Alcohol Alcohol 2006; 41: 261-266 [PMID: 16476762]
120. González-Reimers E, García-Valdecasas-Campelo E, Santolaria-Fernández F, de la Vega-Prieto MJ, Ros-Vilamajó R, Martínez-Riera A, Castellano-Higuera A, Rodríguez-Gaspar M. Pro-inflammatory cytokines in stable chronic alcoholics: relationship with fat and lean mass. Food Chem Toxicol 2007; 45: 904-909 [PMID: 17210215 DOI: 10.1016/j.fct.2006.11.012]
121. Gonzalez-Calvin JL, Gallego-Rojo F, Fernandez-Perez R, Casado-Caballero F, Ruiz-Escolano E, Olivares EG. Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J Clin Endocrinol Metab 2004; 89: 4325-4330 [PMID: 15356028]
122. Lemmers A, Moreno C, Gustot T, Maréchal R, Degré D, Demetter P, de Nadai P, Geerts A, Quertinmont E, Vercruysse V, Le Moine O, Devière J. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 2009; 49: 646-657 [PMID: 19177575]
123. Otte C, Otte JM, Strodthoff D, Bornstein SR, Fölsch UR, Mönig H, Kloehn S. Expression of leptin and leptin receptor during the development of liver fibrosis and cirrhosis. Exp Clin Endocrinol Diabetes 2004; 112: 10-17 [PMID: 14758566]
124. Piche T, Vandenbos F, Abakar-Mahamat A, Vanbiervliet G, Barjoan EM, Calle G, Giudicelli J, Ferrua B, Laffont C, Benzaken S, Tran A. The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J Viral Hepat 2004; 11: 91-96 [PMID: 14738564]
125. Ormarsdóttir S, Ljunggren O, Mallmin H, Olofsson H, Blum WF, Lööf L. Inverse relationship between circulating levels of leptin and bone mineral density in chronic liver disease. J Gastroenterol Hepatol 2001; 16: 1409-1414 [PMID: 11851841]
126. Szalay F, Folhoffer A, Horváth A, Csak T, Speer G, Nagy Z, Lakatos P, Horváth C, Habior A, Tornai I, Lakatos PL. Serum leptin, soluble leptin receptor, free leptin index and bone mineral density in patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2005; 17: 923-928 [PMID: 16093869]
127. Adami S, Marcocci C, Gatti D. Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res 2002; 17 Suppl 2: N18-N23 [PMID: 12412773]
128. Masiukiewicz US, Insogna KL. The role of parathyroid hormone in the pathogenesis, prevention and treatment of postmenopausal osteoporosis. Aging (Milano) 1998; 10: 232-239 [PMID: 9801733]
129. Kawai M, de Paula FJ, Rosen CJ. New insights into osteoporosis: the bone-fat connection. J Intern Med 2012; 272: 317-329 [PMID: 22702419 DOI: 10.1111/j.1365-2796.2012.02564.x]
130. Canalis E. Update in new anabolic therapies for osteoporosis. J Clin Endocrinol Metab 2010; 95: 1496-1504 [PMID: 20375217 DOI: 10.1210/jc.2009-2677]
131. Marie PJ. Strontium ranelate: a physiological approach for optimizing bone formation and resorption. Bone 2006; 38: S10-S14 [PMID: 16439191]
132. Kinyó Á, Belso N, Nagy N, Pálvölgyi A, Nagy I, Korom I, Varga E, Kemény L, Bata-Csörgo Z. Strontium ranelate-induced DRESS syndrome with persistent autoimmune hepatitis. Acta Derm Venereol 2011; 91: 205-206 [PMID: 21243321 DOI: 10.2340/00015555-1014]
133. Yurci A, Kalkan AO, Ozbakir O, Karaman A, Torun E, Kula M, Baskol M, Gursoy S, Yucesoy M, Bayram F. Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease. Eur J Gastroenterol Hepatol 2011; 23: 1206-1212 [PMID: 21971374 DOI: 10.1097/MEG.0b013e32834cd6f6]
134. Zein CO, Jorgensen RA, Clarke B, Wenger DE, Keach JC, Angulo P, Lindor KD. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 2005; 42: 762-771 [PMID: 16175618]
135. Levy C, Harnois DM, Angulo P, Jorgensen R, Lindor KD. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int 2005; 25: 117-121 [PMID: 15698408 DOI: 10.1111/j.1478-3231.2005.01026. x]
136. Floreani A, Zappala F, Fries W, Naccarato R, Plebani M, D'Angelo A, Chiaramonte M. A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis. J Clin Gastroenterol 1997; 24: 239-244 [PMID: 9252849]
137. Camisasca M, Crosignani A, Battezzati PM, Albisetti W, Grandinetti G, Pietrogrande L, Biffi A, Zuin M, Podda M. Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology 1994; 20: 633-637 [PMID: 8076921]